135 related articles for article (PubMed ID: 8471696)
1. Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
Waldmeier PC; Graf T; Germer M; Feldtrauer JJ; Howald H
Biol Psychiatry; 1993 Mar; 33(5):373-9. PubMed ID: 8471696
[TBL] [Abstract][Full Text] [Related]
2. Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.
Waldmeier PC; Glatt A; Jaekel J; Bittiger H
Clin Neuropharmacol; 1993; 16 Suppl 2():S19-24. PubMed ID: 8313393
[TBL] [Abstract][Full Text] [Related]
3. The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo.
Waldmeier PC; Stöcklin K
Eur J Pharmacol; 1989 Oct; 169(2-3):197-204. PubMed ID: 2806381
[TBL] [Abstract][Full Text] [Related]
4. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
Waldmeier PC
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Celada P; Pérez J; Alvarez E; Artigas F
J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
[TBL] [Abstract][Full Text] [Related]
8. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
[TBL] [Abstract][Full Text] [Related]
9. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.
Bel N; Artigas F
Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):475-82. PubMed ID: 7543977
[TBL] [Abstract][Full Text] [Related]
10. The effects of brofaromine, a reversible MAO-A inhibitor, on extracellular serotonin in the raphe nuclei and frontal cortex of freely moving rats.
Celada P; Bel N; Artigas F
J Neural Transm Suppl; 1994; 41():357-63. PubMed ID: 7931251
[TBL] [Abstract][Full Text] [Related]
11. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
12. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
Fahlén T; Nilsson HL; Borg K; Humble M; Pauli U
Acta Psychiatr Scand; 1995 Nov; 92(5):351-8. PubMed ID: 8619339
[TBL] [Abstract][Full Text] [Related]
13. Brofaromine--a review of its pharmacological properties and therapeutic use.
Volz HP; Gleiter CH; Waldmeier PC; Struck M; Möller HJ
J Neural Transm (Vienna); 1996; 103(1-2):217-45. PubMed ID: 9026374
[TBL] [Abstract][Full Text] [Related]
14. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.
Davis BA; Kennedy SH; Durden DA; D'Souza J; Goldbloom DS; Boulton AA
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Sep; 17(5):747-63. PubMed ID: 7504824
[TBL] [Abstract][Full Text] [Related]
15. Regional action of brofaromine on rat brain MAO-A and MAO-B.
Gerardy J; Dresse A
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1141-55. PubMed ID: 9829294
[TBL] [Abstract][Full Text] [Related]
16. Effect of fluvoxamine on 5-hydroxytryptamine uptake, paroxetine binding sites and ketanserin binding sites in the Japanese monkey brain and platelets, in vivo and in vitro.
Goto S; Egashira T; Wada Y; Takayama F; Yamanaka Y
Jpn J Pharmacol; 1996 Aug; 71(4):291-8. PubMed ID: 8886926
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.
Kennedy SH; Davis BA; Brown GM; Ford CG; d'Souza J
Neurochem Res; 1993 Dec; 18(12):1281-5. PubMed ID: 7505890
[TBL] [Abstract][Full Text] [Related]
18. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
19. Brofaromine, a drug inhibiting MAO-A and 5-HT uptake.
Waldmeier PC; Feldtrauer JJ; Graf T; Howald H
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():341A-342A. PubMed ID: 1498863
[No Abstract] [Full Text] [Related]
20. Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression.
Steiger A; Holsboer F; Gerken A; Demisch L; Benkert O
Pharmacopsychiatry; 1987 Nov; 20(6):262-9. PubMed ID: 3432361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
